Suppr超能文献

相似文献

1
Parkinsonism without dopamine neuron degeneration in aged l-dopa-responsive dystonia knockin mice.
Mov Disord. 2017 Dec;32(12):1694-1700. doi: 10.1002/mds.27169. Epub 2017 Sep 26.
2
A new knock-in mouse model of l-DOPA-responsive dystonia.
Brain. 2015 Oct;138(Pt 10):2987-3002. doi: 10.1093/brain/awv212. Epub 2015 Jul 27.
4
Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia.
Brain. 2009 Jul;132(Pt 7):1753-63. doi: 10.1093/brain/awp084. Epub 2009 Jun 2.
5
Novel compound heterozygous synaptojanin-1 mutation causes l-dopa-responsive dystonia-parkinsonism syndrome.
Mov Disord. 2017 Mar;32(3):478-480. doi: 10.1002/mds.26876. Epub 2016 Nov 21.
7
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Neuropharmacology. 2020 Jan 1;162:107829. doi: 10.1016/j.neuropharm.2019.107829. Epub 2019 Oct 24.
8
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
Mov Disord. 2017 Apr;32(4):538-548. doi: 10.1002/mds.26955. Epub 2017 Mar 3.
9
Brain catecholamine depletion and motor impairment in a Th knock-in mouse with type B tyrosine hydroxylase deficiency.
Brain. 2015 Oct;138(Pt 10):2948-63. doi: 10.1093/brain/awv224. Epub 2015 Aug 14.
10
Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys.
Cell Transplant. 2007;16(3):229-44. doi: 10.3727/000000007783464704.

引用本文的文献

1
Striatal cell-type-specific molecular signatures reveal potential therapeutic targets in a model of dystonia.
Neurobiol Dis. 2025 Aug;212:106981. doi: 10.1016/j.nbd.2025.106981. Epub 2025 May 28.
2
Clinical and Basic Research on Dopa-Responsive Dystonia: Neuropathological and Neurochemical Findings.
Juntendo Med J. 2025 Jan 30;71(1):2-10. doi: 10.14789/ejmj.JMJ24-0023-R. eCollection 2025.
3
Striatal cell-type-specific molecular signatures reveal therapeutic targets in a model of dystonia.
bioRxiv. 2024 Oct 7:2024.10.07.617010. doi: 10.1101/2024.10.07.617010.
4
Synaptic Dysfunction in Dystonia: Update From Experimental Models.
Curr Neuropharmacol. 2023;21(11):2310-2322. doi: 10.2174/1570159X21666230718100156.
5
7
GCH-1 genetic variant may cause Parkinsonism by unmasking the subclinical nigral pathology.
J Neurol. 2020 Jul;267(7):1952-1959. doi: 10.1007/s00415-020-09788-2. Epub 2020 Mar 13.
8
Roles of the M acetylcholine receptor in the basal ganglia and the treatment of movement disorders.
Mov Disord. 2019 Aug;34(8):1089-1099. doi: 10.1002/mds.27740. Epub 2019 Jun 18.
9
Striatal Cholinergic Interneurons in a Knock-in Mouse Model of L-DOPA-Responsive Dystonia.
Front Syst Neurosci. 2018 Jun 27;12:28. doi: 10.3389/fnsys.2018.00028. eCollection 2018.

本文引用的文献

1
Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease.
Neurology. 2017 Apr 11;88(15):1461-1467. doi: 10.1212/WNL.0000000000003810. Epub 2017 Mar 10.
2
Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity.
Neurobiol Aging. 2017 Feb;50:39-46. doi: 10.1016/j.neurobiolaging.2016.10.006. Epub 2016 Oct 13.
3
Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters.
Pharmacol Rev. 2016 Oct;68(4):888-953. doi: 10.1124/pr.115.012260.
4
A new knock-in mouse model of l-DOPA-responsive dystonia.
Brain. 2015 Oct;138(Pt 10):2987-3002. doi: 10.1093/brain/awv212. Epub 2015 Jul 27.
5
Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release.
Neuroimage. 2015 Nov 1;121:20-8. doi: 10.1016/j.neuroimage.2015.07.035. Epub 2015 Jul 21.
6
Dopa-responsive dystonia--clinical and genetic heterogeneity.
Nat Rev Neurol. 2015 Jul;11(7):414-24. doi: 10.1038/nrneurol.2015.86. Epub 2015 Jun 23.
7
Novel GCH1 variant in Dopa-responsive dystonia and Parkinson's disease.
Parkinsonism Relat Disord. 2015 Apr;21(4):394-7. doi: 10.1016/j.parkreldis.2015.01.004. Epub 2015 Jan 14.
9
Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.
Brain. 2014 Sep;137(Pt 9):2480-92. doi: 10.1093/brain/awu179. Epub 2014 Jul 2.
10
Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.
Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9977-82. doi: 10.1073/pnas.1402134111. Epub 2014 Jun 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验